FDA Approves Secukinumab as First IL-17 Biologic for Polymyalgia Rheumatica
The FDA approved Novartis' secukinumab (Cosentyx) 150 mg for polymyalgia rheumatica (PMR) in adults with inadequate corticosteroid response. The approval follows phase 3 trial results showing sustained remission in 40.5% of patients vs. 20.5% on placebo. Secukinumab is the first IL-17 biologic approved for PMR, offering a new treatment option with a steroid-sparing effect.
How this was made

The 30-second read
Why it matters
The FDA approval of secukinumab 150 mg for steroid-inadequate or steroid-intolerant PMR patients introduces a new mechanism (IL-17A inhibition) and provides trial-backed sustained remission and steroid-sparing data, but with notable infection-related safety considerations.
Market read
Traders can treat this as a same-day label expansion catalyst for Novartis’s Cosentyx, with quantifiable efficacy and safety details that affect near-term sentiment and longer-term commercial modeling.
What to watch
Real-world uptake will depend on clinician comfort with infection screening/vaccination protocols and payer reimbursement for biologics in PMR, especially given the steroid-taper context.
Background
PMR is a steroid-dependent inflammatory condition in adults 50+, with relapse during taper driving prolonged glucocorticoid exposure and associated risks.
Ticker impact
FDA approved secukinumab (Cosentyx) 150 mg for polymyalgia rheumatica, making it the first IL-17 biologic approved for this indication.
Likely positive repricing as investors model new PMR uptake and reduced reliance on corticosteroids.
The article is a direct FDA approval with specific efficacy and safety outcomes, which is typically material for the branded drug’s commercial outlook.
Market effects
Reinforces IL-17 biologics’ expanding role in inflammatory rheumatology and may intensify competitive positioning versus existing IL-6 pathway options.
Primarily US regulatory-driven demand expectations for a globally marketed biologic.
Could accelerate global uptake discussions and payer coverage planning for PMR beyond the US.
Counterpoint
Infection and hypersensitivity signals (UTIs, cryptococcal meningitis) could limit real-world adoption versus corticosteroids or IL-6 options, tempering commercial upside.
Key entities
- drugsecukinumab
Cosentyx IL-17A biologic approved for PMR at 150 mg in steroid-inadequate or steroid-taper-intolerant adults.
- productCosentyx
Novartis-branded secukinumab; first FDA-approved IL-17 biologic for PMR per the article.
- clinical_trialREPLENISH trial
Phase 3 randomized, double-blind, placebo-controlled study in recently relapsed PMR; sustained remission and steroid exposure outcomes reported.
- regulatorFDA
Approved secukinumab 150 mg for PMR on Nov. 17, 2026.



